Soligenix Reports Positive Extended Phase 2a Results for SGX302 Gel in Psoriasis Treatment

Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, reported extended results from its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel was well tolerated with no drug-related adverse events and demonstrated improvements across multiple clinical and quality-of-life measures, including Investigator Global Assessment and Psoriasis Area and Severity Index scores, with results comparable to or exceeding those observed with the prior ointment formulation. These findings support continued development of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic option for psoriasis.

The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 in Behcet's Disease.

Soligenix's Public Health Solutions business segment includes development programs for RiVax(R), a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola and CiVax(TM), a vaccine candidate for COVID-19 prevention. The development of these vaccine programs incorporates proprietary heat stabilization platform technology known as ThermoVax(R). This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

The latest news and updates relating to SNGX are available in the company's newsroom at https://nnw.fm/SNGX. NetworkNewsWire (NNW) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release services, social media distribution, and corporate communications solutions. For more information, please visit https://www.NetworkNewsWire.com. Full terms of use and disclaimers are available on the NetworkNewsWire website applicable to all content provided by NNW.